Download - Genetiksignal_crowdfund
Discovery of novel cosmeceuticals (cosmetic products that have medicinal or drug-like benefits) and nutraceuticals (dietary supplement or food ingredient) by innovative anti-aging methods for healthy aging in skincare and nutrition
THE NEXT INGREDIENT IN ANTI-AGING SKIN CARE
Chemical peels
Exfoliants
CoQ10Niacinamide
Peptides (EGF)
Retinol
Sunscreen ingredients
Botox
Hyaluronic acid
Probiotics
Microalgal
Resveratrol
Stem cells
Anti-agingSkincareCompositions
ingredients
MODULATOR
“cosmeceutical” refers to cosmetic products that have medicinal or drug-like benefits
GENETIKSIGNAL ANTI-AGING INNOVATION
DIETARY/ CALORIC
RESTRICTION
mTORC1
MITOCHONDRIA
Free radicals
ANTIOXIDANTS
Aging
Enzymes (collagen, elastin)
mRNA TRANSLATION
AUTOPHAGY
Aging can be slowed: Dietary restriction
DR in yeast accomplished by decreasing glucose concentration from 2% to 0.5% or lower
VALUE PROPOSITION
Exclusive license for
IP; methods U. S. patents
ChemoPreventativ
eNon-
carcinogen
No FDA approval
for cosmeceuti
cal
Low cost of starting
compounds modulaTORdiscovery portfolio
Naturally derived next genantioxidants
MARKET OPPORTUNITYCosmeceuticals, Nutraceuticals
* Technology Insight Report – Antiaging skin care compositions –Patent InSight Pro (2010)
Cosmeceuticals –US industry study with forecasts for 2015 & 2020 by Freedonia Group, July 2011
Anti-aging• Global market for anti-aging products (which
includes pharmaceutical products for age related health issues, supplements and appearance based products which include skin care) is an estimated $291.9 billion by the year 2015 *
0
50
100
150
200
250
300
350
$ m
illio
ns
Vitamin A
Vitamin E
Vitamin C
CoQ10
$700 million cosmeceutical skin care antioxidant market by 2017
BUSINESS MODEL
Sponsored
research
CROs
Strategic partners
Distributed partnering model(Kauffman foundation)
Product Definitio
n Compan
y
Discovery
Definition
Development
Delivery
IN-LICENSING
OUT-LICENSING
BUSINESS STRATEGY
YEAR 1
• COMPOUND IDENTIFICATION
• IN VITRO ANTI-AGING YEAST SCREENS
YEAR 2
• MAMMALIAN/ SKIN FIBROBLAST IN VITRO SCREENS
• CRO• MARKETING
YEAR 3
• PRODUCTION• MANUFACTURI
NG• FORMULATION
AND DELIVERY
VALUE INFLECTION “COSMECEUTICAL DISCOVERY”
SERIES A ROUND
VALUE CREATION REVENUE
(CUSTOMER)ROI IS 5-10X
Strategic Alliances/ Partners:Cosmetics companies (Cosmeceuticals)Pharma consumer health companies (Nutraceuticals)
GENETIKSIGNAL ASSETS
MANAGEMENT TALENT:CSO/CEO: GINA DEVASAHAYAM, BIOENTREPRENEUR
VP-CHEMISTRY: RYAN VAN DE WATER, MEDICINAL CHEMIST
SCIENTIFIC ADVISORY BOARD: MATT KAEBERLEIN, ASSOCIATE PROFESSOR FRANCIS BURROWS, CSO, AARDEN PHARMA
LEGAL COUNSEL: CHARLES KATZ, EMERGING COMPANY & VC PRACTICE, MORRISON & FOERSTER
BUSINESS ADVICE AND CONSULTING: INNOVATE PROGRAM (JHU, UMBC, MARYLAND)
PROPRIETARY INTELLECTUAL ASSET: IP FROM UNIVERSITY OF WASHINGTON, SEATTLE
THANK YOU!
www.genetiksignal.com